logo
'Not How Numbers Work': Critics School Trump After Baffling New Claim

'Not How Numbers Work': Critics School Trump After Baffling New Claim

Yahoo5 days ago
President Donald Trump is getting heat on social media for making a claim on Tuesday about cutting drug prices that's essentially mathematically impossible.
Trump began promisingly enough with a complaint shared by Democrats and Republicans alike: the high cost of medication, and how much more Americans pay for some medications than patients in other countries.
He promised to reduce those costs ― but to a very unlikely degree.
'We're gonna get the drug prices down. Not 30% or 40%, which would be great. Not 50% or 60%. No, we're gonna get them down 1,000%, 600%, 500%, 1,500%,' Trump said at a Republican dinner. 'Numbers that are not even thought to be achievable.'
Critics quickly pointed out the reason those numbers are not thought to be achievable: reducing the price by 100% would make the drugs free. Reducing it by '1,000%, 600%, 500%, 1,500%,' as Trump said, would make the cost negative dollars ― with the drug company essentially paying people to take the medication.
Several users asked Grok, the AI chatbot on X, if Trump's numbers made sense. Grok called Trump's claim 'mathematically impossible,' 'hyperbolic and not literal' and 'total bullshit.'
But Trump insisted he could use 'a certain talent that I have' to convince pharmaceutical companies that they have no choice but to reduce their prices.
Trump also mentioned an executive order he signed in May to invoke 'most-favored nation' status in drug costs, which he says would ensure that drug companies can't charge Americans any more than what they charge patients in other nations.
However, the details of that plan remain hazy, and at least one pharmaceutical CEO said discussions with the White House are ongoing and expected to take time.
Trump on Tuesday insisted that his order will lead to those price cuts.
'We will have reduced drug prices by 1,000%, by 1,100, 1,200, 1,300, 1,400, 700, 600,' he said. 'Not 30 or 40 or 50%, but numbers the likes of which you've never even dreamed of before.'
Trump's critics offered some free math lessons:
As someone who graduated from first grade, this is not how numbers work. https://t.co/dx4lMcQTAb
— Hemant Mehta (@hemantmehta) July 23, 2025
Thank goodness this guy isn't negotiating the percentages we pay in tariffs. https://t.co/x7EppKShSq
— Justin Wolfers (@JustinWolfers) July 23, 2025
Quite a trick if he can do it. Are we going into negative numbers where big Pharma pays me to take their drugs?
— Dj Omega Mvp (@DjOmegaMVP) July 23, 2025
Hard to imagine this guy was found liable of fraud for making up numbers https://t.co/vgjVF1q2DI
— MeidasTouch (@MeidasTouch) July 23, 2025
The economics department at Wharton must be incredibly proud of this man's fundamental understanding of basic math. https://t.co/kuwIorU8TL
— Franklin Leonard (@franklinleonard) July 23, 2025
Cant wait fill my next zpack at cvs and leave with a stack of their money https://t.co/EgT12GMTul
— Ronnie (@Gem_Mint_Cards_) July 23, 2025
Getting paid to take drugs sounds awesome where do I sign up
— TCL (@TitleTalkTCL) July 23, 2025
Universal Prescription Income. Your move, Yang https://t.co/7QbV09x3Xe
— Roger Sollenberger (@SollenbergerRC) July 23, 2025
What kind of math is this? https://t.co/yu5kzUJEeO
— Wu Tang is for the Children (@WUTangKids) July 23, 2025
And people wonder how this idiot bankrupted casinos. https://t.co/5xtlIrj0Gd
— Jo (@JoJoFromJerz) July 23, 2025
Negative drug prices are on the way ! 🤣🇺🇸 https://t.co/HLflM8fdZK
— Christopher Schultz (@nalyticsatwork) July 23, 2025
This is the fucking genius. https://t.co/JkEHJbqB01
— Fred Wellman (@FPWellman) July 23, 2025
https://t.co/4XedIgYgi8pic.twitter.com/OBOgCBZNii
— Dave Itzkoff (@ditzkoff) July 23, 2025
@realDonaldTrump is out here pitching drug deals like it's Shark Tank for Cartels:'I'm offering insulin for negative $300 and a lifetime supply of bleach injections… but only if you call in the next 15 minutes.'This QVC for crackheads.
— Frank C (@FrankC164) July 23, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Yahoo

time19 minutes ago

  • Yahoo

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

The Open Group Launches The Open Group Open Digital Transformation™ Forum
The Open Group Launches The Open Group Open Digital Transformation™ Forum

Yahoo

time19 minutes ago

  • Yahoo

The Open Group Launches The Open Group Open Digital Transformation™ Forum

Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Yahoo

time19 minutes ago

  • Yahoo

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store